您当前所在的位置:首页 > 产品中心 > 产品信息
Dextromethorphan_分子结构_CAS_125-71-3)
点击图片或这里关闭

Dextromethorphan

产品号 DB00514 公司名称 DrugBank
CAS号 125-71-3 公司网站 http://www.ualberta.ca/
分子式 C18H25NO 电 话 (780) 492-3111
分子量 271.3972 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 396

产品价格信息

请登录

产品别名

标题
Dextromethorphan
IUPAC标准名
(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene
IUPAC传统名
dextromethorphan
商标名
Novahistine DM
Cosylan
Creo-Terpin
Balminil DM
Benylin DM 12 Hour
Delsym
Delsym Cough Formula
Diabe-Tuss DM Syrup
Hihustan M.
Koffex DM
Antussan
Benylin Adult Formula Cough Suppressant
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
Calmylin #1
Cough-X
Hold DM
Medicon
Metrorat
Novahistex DM
Pertussin CS Children's Strength
Robitussin Pediatric Cough Suppressant
Romilar
Sucrets 4 Hour Cough Suppressant
Tusilan
Vicks 44 Cough Relief
Balminil DM Children
Benylin DM
Benylin DM for Children
Canfodion
Dormetan
Dormethan
Methorate Hydrobromide
Methorphan
Pertussin DM Extra Strength
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Triaminic DM Long Lasting for Children
Trocal
Tussade
别名
Demorphine
Dexyromethorphan
Levometorfano [INN-Spanish]
D-Methorphan
D-Methorphan Hydrobromide
Demorphan
Levomethorphanum [INN-Latin]
Dextromethorfan [Czech]
Dextromethorphan Bromhydrate
Dextromethorphan Bromide
Dextromorphan
L-Methorphan
Levomethorphane [INN-French]
Delta-Methorphan
Destrometerfano [Dcit]
Demorphan Hydrobromide
Dextrometorfano [INN-Spanish]
Dextrometorphan
Levomethorphan
Levomethorphan [Ban:Dcf:Inn]

产品登记号

CAS号 125-71-3

产品性质

疏水性(logP) 3.6
溶解度 74.7 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity. [PubChem]
Indication For treatment and relief of dry cough.
Pharmacology Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. Rapidly and extensively metabolized to dextrorphan (active metabolite). One well known metabolic catalyst involved is a specific cytochrome P450 enzyme known as 2D6, or CYP2D6.
Absorption Rapidly absorbed from the gastrointestinal tract.
Half Life 3-6 hours
References
Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70. [Pubmed]
Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989 Jun 16;244(4910):1360-2. [Pubmed]
Hargreaves RJ, Hill RG, Iversen LL: Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-9. [Pubmed]
Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL: Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. Neurotoxicology. 2007 Jul;28(4):813-8. Epub 2007 Apr 6. [Pubmed]
Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ: Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000 Jun;293(3):962-7. [Pubmed]
External Links
Wikipedia
Drugs.com

参考文献

  • Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70. Pubmed
  • Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989 Jun 16;244(4910):1360-2. Pubmed
  • Hargreaves RJ, Hill RG, Iversen LL: Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-9. Pubmed
  • Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL: Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. Neurotoxicology. 2007 Jul;28(4):813-8. Epub 2007 Apr 6. Pubmed
  • Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ: Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000 Jun;293(3):962-7. Pubmed